Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Overview of attention for article published in Lancet Neurology, October 2026

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

bluesky: 3 Bluesky users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 3 Bluesky posts from 3 Bluesky users, with an upper bound of 2,261 followers.

RP @thelancetneuro.bsky.social: In our October issue: results of HIMALAYA, an international phase 2 trial of the oral RIPK1 inhibitor SAR443820 for amyotrophic lateral sclerosis www.thelancet.com/journals/lan...

In our October issue: results of HIMALAYA, an international phase 2 trial of the oral RIPK1 inhibitor SAR443820 for amyotrophic lateral sclerosis www.thelancet.com/journals/lan...

[Articles] Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, pha #NeuroDegeneration 🧪🧠 https://www.thelancet.com/journals/laneur/ar…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.